1. POLATUZUMAB VEDOTIN PLUS BENDAMUSTINE AND RITUXIMAB OR OBINUTUZUMAB IN RELAPSED/REFRACTORY FL OR DLBCL: UPDATED RESULTS OF A PHASE 1B/2 STUDY. (June 2017) Authors: Matasar, M.; Herrera, A.F.; Kamdar, M.; Mehta, A.; Assouline, S.; Fleury, I.; Kim, T.M.; Kim, W.S.; Bosch, F.; Radford, J.; Flowers, C.R.; Bu, L.; Hong, W.; Sehn, L.H. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 271 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P1192: ASIA SUBPOPULATION ANALYSIS FROM THE PHASE III POLARIX TRIAL. (23rd June 2022) Authors: Song, Y.; Jin, J.; Tilly, H.; Zhang, H.; Cao, J.; Feng, J.; Zhang, L.; Rai, S.; Goto, H.; Terui, Y.; Kim, W. S.; Shin, H.-J.; Gau, J.-P.; Tsai, C.-H.; Sharman, J. P.; Bu, L.; Hirata, J.; Lee, C.; Izutsu, K.; Zhu, J. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 1078 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Retraction of: abstract P71, In vitro and in vivo direct monitoring of miRNA-22 expression in isoproterenol-induced cardiac hypertrophy by bioluminescence imaging. Issue 2 (25th November 2014) Authors: Tu, Y.; Wan, L.; Bu, L.; Shen, B. Journal: Cardiovascular research Issue: Volume 113: Issue 2(2017) Page Start: 248 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Retraction of: abstract P71, In vitro and in vivo direct monitoring of miRNA-22 expression in isoproterenol-induced cardiac hypertrophy by bioluminescence imaging. Issue 2 (25th November 2014) Authors: Tu, Y.; Wan, L.; Bu, L.; Shen, B. Journal: Cardiovascular research Issue: Volume 113: Issue 2(2017) Page Start: 248 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗